Company intelligence / Profile preview

Marigot

Ownership: Private
Employees: ~127
Development stage: Commercial

Overview

Aquamin has been supported by an established scientific program demonstrating efficacy in bone, joint, cognitive and digestive health. Peer-reviewed research supports its use for these indications. Academic collaborations have investigated mechanisms such as inhibition of intestinal carbohydrate digestive enzymes to support metabolic benefits.

Therapeutic areas: Metabolic DisordersEndocrinologyRheumatologyGastroenterologyNeurology
Modalities: Mineral complexMarine multi-mineralsPlant protein ingredients
Industry: Food & Nutrition

Partnerships

University College Dublin (UCD) – SFI Strategic Partnership Award (Bio-PADT project)Centre for Applied Bioscience Research

Beyond the preview

Go deeper on Marigot.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marigot.

Explore the full profile